Recent Trends Diabetes And Case Study Of Diabetic Patients

Mahesh Raghunath Tathe, Anant Anil Pardeshi, Ram Ingle

Institue Name: Nandkumar Shinde College Of Pharmacy, Vaijapur. Dist. Aurangabad,

ABSTRACT

The frequency of patients with type 2 diabetes (DM), a chronic metabolic condition, has been continuously rising worldwide. Due to this trend, it is quickly turning into such an epidemic in the some countries around the world, with the number of affected individuals predicted to double in the following decade due to an ageing population, adding to the burden already placed on healthcare providers, particularly in developing nations. The Medline, Cochrane Database of Systematic Reviews, or citation lists of pertinent publications were searched for this review. Type 2 diabetes mellitus, its prevalence, current diagnosis, or current therapy are included in the subject heading and key terms employed. Only English-language articles were included. The World Health Organization's (WHO) or American Diabetic Association (ADA) guidelines, which take into account both laboratory and clinical factors, continue to form the foundation for screening and diagnosis. The illness has no known cure as of yet. Nonetheless, there are a variety of therapy options available, including dietary changes, obesity management, oral hypoglycemic medications, or insulin sensitizers such metformin, a biguanide which lowers insulin resistance and is still the go-to drug, particularly for obese individuals.

Keywords: *Type 2 diabetes mellitus, Diagnosis, Management, Newer drugs*.

Introduction:

One of the most prevalent non-communicable diseases in the world is diabetes mellitus. The global health of people is represented by diabetes, a leading killer (NCD risk factor collaboration, 2016). According to the World Health Organization (WHO), the disease had an alarmingly high prevalence in 2006 with 180 million cases. In addition towards its social or economic situation, it is a significant public health issue. A potential treatment for diabetes remains a far-off goal for diabetic individuals despite a large literature filled with research on the condition. Hence, the review of recent trends on diabetes, therapeutic strategies, and management for diabetes mellitus using stem cell, gene, and nanotechnology, as well as a case study on diabetic patient care. Treatment and complications for covid-19 illness and diabetes. This article focuses mostly on recent trends as a result of an overall rise in the prevalence of diabetes mellitus. Important aspects of diabetes diagnosis, treatment, and patient care are covered. Diabetes mellitus, commonly referred to as just diabetes, is a set of metabolic illnesses characterised by persistently elevated blood sugar levels. The symptoms of this high blood sugar include frequent urination, extreme thirst, and increased appetite. - Diabetes has a lot of problems if left untreated. Diabetic ketoacidosis or nonketotic hyperosmolar coma are examples of acute complications. - Heart disease, stroke, kidney failure, foot ulcers, and eye damage are examples of serious long-term consequences. Diabetes results from either insufficient insulin production by the pancreas or improper insulin utilisation by the body's cells.

There are three main types of diabetes mellitus:

1. Type 1 DM
2. Type 2 DM
3. Gestational DM

Type 1 DM: Due to inadequate insulin production by the body. Previously, this condition was referred to as "juvenile diabetes" or "insulin-dependent diabetes mellitus" (IDDM).

Type 2 DM: Starts with insulin resistance, the condition in which cells do not react appropriately to insulin. In addition, a shortage of insulin may occur as the condition worsens. This condition was once known as "adult-onset diabetes" or "non-insulin-dependent diabetes mellitus" (NIDDM). Lack of exercise and high body weight are the main contributors.

Gestational diabetes: Is the third main type, and it happens when pregnant women who have never had diabetes have high blood sugar levels.

Sign and symptoms: Weight loss, frequent urination, increased thirst, and polyphagia are the typical signs of untreated diabetes (increased hunger). With type 1 diabetes, symptoms may appear suddenly (within weeks or months), whereas they do so much more gradually in diabetes with type 2 and may even not appear at all. Although they're not specific to a disease, a number of additional symptoms and signs can indicate the beginning of diabetes. These also include fatigue, headaches, blurred vision, itchy skin, and poor wound healing as addition to the previously mentioned symptoms. Long-term high blood sugar levels can cause your eye's lens to absorb glucose, changing its shape and impairing vision. Diabetes-related skin rashes are commonly referred to as diabetic dermadromes. Hyperosmolar nonketotic condition, more prevalent in type 2 diabetes and mostly brought on by dehydration, is an uncommon but equally dangerous scenario.

Prevention and treatment:

1.] Healthy eating, exercising, quitting smoking, and maintaining an normal body weight. Controlling blood pressure and taking care of one's feet properly are also crucial for those with the disease. Type 1 diabetes must be managed with insulin injections.

2.] Insulin may or may not be used in the treatment of type 2 diabetes. Low blood sugar levels can be brought on by oral medicines and insulin.

3.] Others with type 2 DM who are obese can benefit from weight loss surgery.

4.] Usually, gestational diabetes goes away after the baby is born.

Complication:

The main long-term issues are related to blood vessel damage. Cardiovascular disease is two times more likely in people with diabetes, and coronary artery disease accounts for around 75% of diabetic deaths. Stroke or peripheral vascular disease are two other "macrovascular" conditions. Damage to a eyes, kidneys, or nerves are among the main microvascular consequences of diabetes. Destruction to a blood vessels found in the retina of a eye, or diabetic retinopathy, results in eye damage that can cause gradual vision loss or even blindness. Diabetic nephropathy, or harm to the kidneys, can cause tissue scarring, protein loss in the urine, and finally chronic renal disease, necessitating dialysis or kidney transplantation occasionally. The most frequent side effect of diabetes is diabetic neuropathy, which causes damage to the body's nerves. Numbness, tingling, discomfort, and changed pain perception are some of the signs that can cause skin injury. Diabetes-related foot issues, such diabetic foot ulcers, can develop, are sometimes difficult to treat, and necessitate amputation. Furthermore, painful muscular atrophy and weakness are 2 other symptoms of proximal diabetic neuropathy.

Causes:

Types 1, type 2, gestational, and various particular kinds of diabetes mellitus are divided into these four basic classifications. There are around a dozen different factors that make up the "other specific categories." Often, diabetes mellitus is referred to simply as "diabetes."

Type 1 diabetes mellitus:

It is characterised by the loss of the pancreatic islets of Langerhans' insulin-producing beta cells, which results in insulin insufficiency. This kind can also be divided into immune-mediated and idiopathic subtypes. The majority of diabetes of type 1 is immune-mediated, in which an autoimmune onslaught mediated by T cells results in the death off beta cells and subsequently insulin. Although type 1 diabetes can affect both children and adults, it was historically referred to as "juvenile diabetes" because the majority of occurrences of the disease affected kids. The risk of type 1 diabetes has known to be influenced by a number of genes, including specific HLA genotypes. One or even more environmental variables, like a viral illness or nutrition, can cause diabetes

to develop in individuals who are genetically predisposed to the disease. Some evidence points to a connection between Coxsackie B4 virus and type 1 diabetes. This onset is type 1 diabetes was independent to lifestyle choices, unlike type 2 diabetes. The phrase "brittle" diabetic, also called as unstable diabetes and labile diabetes, was historically used to characterise the pronounced and frequent swings in blood sugar levels in insulin-dependent diabetes, which frequently occur for no apparent reason. Therefore, this phrase should not be utilised because it lacks a biological foundation. Yet, diabetes with type 1 can also be accompanied by unexpected and erratic hyperglycemia, ketosis often, and occasionally severe hypoglycemia. Additional issues include a defective response to hypoglycemia's counterregulatory mechanism, illness, gastroparesis (which causes irregular dietary glucose absorption), and endocrinopathies (such as Addison's disease). These occurrences are thought to be limited to 1% to 2% of those who have type 1 diabetes.

Type 2 diabetes mellitus:

It is distinguished with insulin resistance, which could also be accompanied by noticeably less insulin production. The insulin receptor is thought to play a role in the impaired sensitivity of bodily tissues to insulin. The precise flaws, however, are unknown. Cases of diabetes mellitus with a recognised defect are given a different classification. The most prevalent type of diabetes is type 2.

The main causes of type 2 diabetes are genetics and lifestyle choices. Obesity is one lifestyle factor that is known to play a significant role in the emergence of type 2 diabetes. Lack of exercise, a bad diet, stress, and urbanisation are all contributing factors to obesity (defined as being overweight with a body mass index if greater than 30). 30% of instances in people having Chinese and Japanese ancestry, 60%–80% of cases in people of European or African ancestry, and 100% of cases in Pima Indians or Pacific Islanders are linked to excess body fat. Many people who aren't obese have a large waist-to-hip ratio.

Diagnosis:

Recurrent or chronic hyperglycemia, a feature of diabetes mellitus, can be detected by any of the signs and symptoms listed below.

7.0 mmol/l (126 mg/dl) of fasting plasma glucose.

Two hours following a 75 g dose of oral glucose as in a test for glucose tolerance, plasma glucose should be less than 11.1 mmol/l (200 mg/dl).

Hyperglycemia symptoms and routine blood sugar levels of less than 11.1 mmol/l (200 mg/dl). For type 1 diabetes, there is no proven preventive intervention. A person can frequently avoid developing type 2 diabetes by maintaining a healthy weight, engaging in regular exercise, and eating a balanced diet. A diet high in whole grains and fibre as well as the selection of healthy fats, including the polyunsaturated fats that are found in fish, nuts, and vegetable oils, are known to be useful in preventing diabetes. [48] Diabetes can also be prevented by limiting sugary drinks and consuming lesser red meat as well as other forms of saturated fat. [48] Quitting smoking can be a significant preventive intervention because active smoking is linked to the an increased risk in developing diabetes.

Managements:

Except in very limited circumstances, there isn't a known cure for the chronic condition diabetes mellitus. The goal of management is to maintain "euglycemia," or blood sugar levels that are as close to normal as possible, without resulting in hypoglycemia. Usually, diet, exercise, and the usage of the right drugs can achieve this. (In the event of type 1 diabetes, insulin is used; for type 2 diabetes, oral medicines and perhaps insulin are used). Insulin is used to treat type 1 diabetes; oral medications and maybe insulin are used to treat type 2.

Lifestyle:

With the aim of maintaining both short and long blood glucose levels below acceptable ranges, people given diabetes may benefit from education on the condition and its treatment, adequate nutrition to reach a healthy weight, and sensible exercise. In addition, lifestyle changes are advised to lower blood pressure due to the increased risks for cardiovascular disease that are connected with them.

Medication:

As there is strong evidence that metformin lowers mortality, it is typically advised as the first line of treatment in type 2 diabetes. However, it has not been discovered that regular aspirin use improves outcomes in simple diabetes.

Regular insulin or NPH insulin, or artificial insulin analogues, are frequently used in the treatment of type 1 diabetes. When type 2 diabetes is treated with insulin, an long-acting formulation is typically administered initially while oral medicines are kept up. Insulin doses are then raised to have effect.

Recent Trends in Diabetes:

1. STEM CELL THERAPY:

The search for a potential treatment for diabetes has led researchers to investigate a number of new scientific fields, one of which is stem cell technology.

2. It is well recognised but both types 1 as well as type 2 diabetes are brought on by a lack of pancreatic cells, which prevents enough insulin from being secreted. The tactics should work to either correct pancreatic cell abnormalities or increase the body's cells' receptivity to insulin.

3. While current efforts aimed at islet cells and pancreatic transplantation are constrained by a lack of organ donors, cell replacement strategies provide an unusual source.

4. In contrast with category 1 diabetes, which would be brought on by the autoimmune death of pancreatic beta cells, category 2 diabetes is brought on by abnormalities in beta cell function combined with peripheral organ insulin resistance.

5. Due to it's own immunosuppressive properties, mesenchymal stem cells (MSC) treatment is a promising therapeutic for the treatment for type 1 diabetes. MSCs have been discovered to exhibit immunomodulatory effects due to direct interaction and generation of soluble markers in both in vitro and in vivo settings.

6. Many mesenchymal cell lineages are capable of developing from MSCs. These cells are multipotent stem cells with the ability to develop into all blood cell types and have immunomodulatory properties.

7. Hematopoietic stem cell transplantation has emerged as a promising treatment, improving cell function for recently diagnosed type 1 diabetes patients.

8. Further research has shown that type 1 diabetes patients can produce induction pluripotent stem (iPS) cells through reprogramming the adult fibroblasts using three transcriptional factors (OCT4, SOX2, and KLF4).

9. DiPS, or diabetes-induced pluripotent stem cells, are pluripotent cells with the capacity to develop into cells that produce insulin. This is advantageous for cell replacement therapy and mimicking type 1 illness.

10. Several studies have demonstrated that bone marrow-derived MSCs can develop into cells that produce insulin in both vitro and in vivo.

11. According to their pluripotent nature or extensive production of many cell lineages in cultures, humans embryonic stem cells (ESCs) are significant in the treatment of diabetes.

12. The lack of trustworthy methods for producing particular cell varieties, immunological rejection of transplanted cells, and difficulties in separating out particular lineages are just a few of the research's problems.

13. Other issues include the embryonic stem cells' unchecked ability to proliferate into a particular type after transplantation. The use of stem cell therapy holds enormous potential for treating diabetes, even with all of its numerous ethical and technical constraints.

Gene Therapy:

1.The set of experiments that resulted in the cloning and production of insulin in cultured cells inside the 1970s represented a significant advancement in medicine, and the use of gene therapy to treat diabetes was proposed as a potential treatment option.

2. The most crucial part of treatment, which also lessens the difficulties related to the illness, is controlling sugar levels. There are two ways to deliver genes in somatic gene therapy, which uses somatic cells in the body.

3. Ex vivo gene therapy involves removing the tissues from the body, inserting the therapeutic gene in vitro, and then reinserting it there, whereas in vivo therapy involves inserting gene therapeutic vectors directly into the patients through subcutaneous, intravenous, intrabronchial, or local injection routes.

4. Ex vivo therapy is used to create cells that have the characteristics of other cells, such as cells that produce insulin.

5. Moreover, this technique has been utilised to produce transplantable cells. The challenge, however, is the idea that surgically removing the patient's tissue and then implanting the genetically altered tissues back into the patient's body.

6. Additionally, islet transplantation has also been investigated as a potential therapy option because type 1 diabetes is caused by the autoimmune death of insulin-producing pancreatic cells. The development of insulin gene therapy provides a potential therapeutic strategy for type 1 diabetes by replacing lost cell function and producing insulin secretory non-cells that are immune system resistant.

7. Because it is easier and allows for direct insertion of the desired gene into the patient, in vivo gene treatment is the preferred therapeutic approach. However, creating safe (host-safe) and efficient vectors is still a difficult problem for gene therapists.

8. Three techniques are now used in in vivo therapy strategies: genetic transfer of genes that lower blood sugar but are not insulin-producing. the application for blood sugar decreasing genes: an amplifier of glucose consumption by liver and skeletal muscles as well as an inhibitor for glucose production even by liver; and genetic transfer for glucose lowering genes that are non-insulin in nature. For instance, it has been discovered that the transgenic glucokinase lowers glucose levels in the liver.

9. It was possible that the Gck gene improves the body's ability to use glucose. Glucokinase genetic transfer has been employed as an adjunctive therapy in the management of diabetes. Another method utilised to control the liver's generation of glucose was using the "protein targeting to glycogen" (PTG) gene to change glucose into glycogen.

10. The PTG protein is a member of the protein phosphatase-1 family with glycogen targeting subunits, which controls the metabolism of glycogen. Rat experiments have shown that adenoviral-mediated PTG transfer promotes the production of glycogen in the liver and lowers blood glucose levels. This has been proposed as a treatment strategy for diabetes.

11. Transfer of genes that respond with glucose and the application of gene therapy to stimulate the creation of liver cells are two further applications of genetic engineering.

12. The glucose-responsive genes that were altered to improve proinsulin to insulin conversion and those whose expression changes result in reactions to blood glucose levels.

13. As the liver cells don't manufacture the hormones that turn proinsulin into insulin, the proinsulin molecule has been modified to include additional proteolytic cleavage sites that can be identified by a protease called furin that is found in various tissue systems, including the liver. The insulin gene could be changed to encode single-chain insulin with 20–40% of the action of mature insulin.

14. Moreover, studies have been done to stimulate the creation of cells in the liver. According to Kojima et al., providing transcription factors unique to islets can cause endocrine cells to produce cells. Since there is a dearth of knowledge regarding insulin metabolism, controlling and regulating the synthesis of insulin remains a challenging undertaking. As it can address the autoimmunity of type 1 diabetes, the technique aiming for induced cells neogenesis appears may be a promising one as a treatment for diabetes.

STATIN THERAPY:

1.Statins are referred to as 3-hydroxy-3-methylglutaryl coenzyme A inhibitors because they stop the vital process of LDL cholesterol in the liver, lowering blood levels of LDL cholesterol while also promoting healthy blood vessel lining.

2. Statins (HMG-CoA reductase inhibitors) are a mainstay of therapy in lowering cardiovascular risk in people with type 2 diabetes since a long-term result of diabetes is a significant risk of cardiovascular illnesses.

3. The lipid-lowering drugs, commonly referred to as statins, specifically and irreversibly inhibit HMG-CoA reductase.

4. The rate-limiting phase in the synthesis of cholesterol, and conversion from HMG-CoA into mevalonic acid, is catalysed by the enzyme. When compared to dietary supplements, these substances are much more effective at lowering cholesterol levels.

5. By significantly lowering lower density lipoprotein (LDL) cholesterol, statin medication significantly lowers the risk of developing coronary artery disease.

6. Lipid lowering therapy was recommended as a Grade A primary preventive measure for patients with type 2 diabetes over the age of 40 by the National Institute of Health and Clinical Excellence (NICE) and the Scottish Intercollegiate Guidance Network (SIGN), as well as for those with type 1 diabetes (Grade B recommendation).

7. Recent data from the European Association of the Investigation of Diabetes meeting in Stockholm reveals that compared to a sizable American cohort of over 100,000 participants, statin medication is being less researched and utilised for patients with type 2 diabetes.

8. In persons with low cholesterol levels and no cardiovascular illness, statins have high efficiency and are useful in reducing cardiovascular events. HMG-CoA reductase inhibitors and statin therapy, however, also has certain drawbacks. The treatment can cause rare, tolerable adverse effects include renal failure, muscle diseases ranging from myositis to extreme rhabdomyolysis, and hepatic dysfunction.

9. The experiment, which had 6422 participants, revealed that young people and those without disease had poor or inadequate adherence to statin therapy. However, since younger patients' poor compliance was seen, the therapy should concentrate on older individuals. Statins should also be given to people who have high health risks and heart disease symptoms.

10. Statins may, however, slightly boost blood sugar levels and cause diabetes mellitus, according to research. Statins may have side effects such myopathies and an increase in the levels of certain liver enzymes, even though they are well tolerated and have few negative consequences.

Medical Nutrition Therapy:

1.Aiming to be using nutrition treatment to treat a variety of ailments and illnesses, medical nutrition therapy makes major advancements in clinical research in the prevention or management of diabetes. The term "medical nutrition therapy," which consists of two phases—determining a person's nutritional needs and providing treatment through counselling and nutrition therapy, respectively—was first used by the American Diabetes Association in 1994.

2. The goals of dietary therapy for diabetes are to maintain a normal range of blood glucose levels, an appropriate body weight, and an optimal amount of lipids in the blood.

3. The effectiveness of nutrition therapy as a treatment for diabetes depends on a number of variables, including the patient's age-based nutritional requirements, food preferences, and other medical conditions, as well as an exercise regimen and recommended dietary needs based on the patient's capabilities and health conditions.

4. For a moderately active person, the daily calorie have to keep ideal body weight is 30-35 kcal/kg; for obese people, it is 20-30 kcal/kg. If caloric intake is decreased by 500 calories per day, it is predicted that steady weight loss of 1 lb per week will take place.

5. Recent recommendations state that the patient's protein and fat consumption determines what percentage of carbohydrates they should consume. Popular low-carb, high-protein diets may result in temporary weight loss and better glycemic control, but they are challenging to follow for extended periods of time. A high-fiber diet with 20–35 g/day of soluble as well as insoluble fibre, sodium restriction of 2400–3000 mg/day, alcohol intake of no more than two drinks per day for men and one drink per day for women, as well as multivitamins should be included in the diet are all recommended. Protein intake is kept at 10–20% of total calories. Total fat intake must be restricted to 30% of total calories.

Herbal Product And Diabetes:

1.Since the dawn of time, literature has advocated using herbal remedies to cure both insulin-dependent and non-insulin-dependent diabetes. Plants with anti-diabetic qualities might work well as a supplement to current treatments or as a potential source of novel hypoglycemic chemicals. Naturopathic treatments have been used for a variety of illnesses since the dawn of time and are still becoming more and more popular today. According to ancient literature, diabetes has been recognised as a disease from the Brahmic period and is mentioned in the fourth and fifth century BC Ayurvedic text Sushrutasamhita.

2. Two types of diabetes are described: one that was hereditary in origin and the other that was brought on by dietary misconduct.

3. Due to their low cost and manageable side effects, herbal medications are growing incredibly popular among the general public. Although plant-based medicines have been utilized for centuries to treat diseases all over the world, most herbs still lack a defined and standardised mechanism of action.

4. Many novel bioactive compounds derived from plants that have hypoglycaemic properties exhibit antidiabetic efficacy comparable to and occasionally even stronger than well-established oral hypoglycaemic medications like daonil, tolbutamide, or chlorpropamide. Many other plant-derived active substances, however, lack adequate characterization.

5. Grover et al. hypothesised that because they are known to have beneficial medical qualities, plants with antidiabetic activity are of great interest to the ethnobotanical community.

6. The anti-diabetic effect of a phytomolecule is significantly influenced by its chemical composition. According to research by Jung et al., certain plant species that are a significant source for terpenoids, flavonoid, phenolics, coumarins, as well as other bioactive components have been proven to lower blood glucose levels.

Nanotechnology:

Nanotechnology is the use of materials and structures that have been molecularly built to monitor, repair, build, and control human biological systems just at cellular level. The application of nanotechnology to medicine is known as nanomedicine, with the goal of improving human health.

Applications for Diabetes Management:

Buccal Insulin:

In contrast to inhalers, the buccal delivery method of insulin administers sugar through with an aerosol into to the oral cavity. Instead of being absorbed by the lungs, the insulin is instead taken in through the back of the mouth as well as the cheeks. The pharmacological efficacy of insulin administered buccally with absorption boosters reached a maximum of 12%.A number of bucco- adhesive formulations, including nanoparticles, have been studied by researchers. Lately, buccal mucosal delivery with insulin utilising bioadhesive formulation has indeed been successfully tried. Oral-lynTM, a liquids formulation for adult regular insulin with a propellant for postprandial insulin therapy, is a formulation of buccal insulin being developed by Generex Biotechnology Company based on Rapid MistTM. The formula produces an aerosol with rather big micelles, the bulk of which are >10 m in size and are therefore too large to enter the lungs. It is stated that each puff will release 10 U if insulin injections. Red insulin has a 10% absorption rate when administered as a puff, which equals 1 U when a puff of 10 U is supplied. As a result, 10 puffs would deliver 10.

Oral Insulin:

Novel insulin carriers have a close relationship with new methods for oral insulin administration. The most practical and recommended route would be the oral one. To get around the issue of daily subcutaneous injections, it is imperative that better oral insulin administration be developed. When insulin is taken orally, gastric enzymes cause it to degrade in the stomach. Moreover, in both in vivo as well as in vitro bioassays have shown that nanoencapsulated insulin is bioactive.

Insulin administered orally to diabetic patients may be helpful not just to lessen the discomfort and stress associated with injections but also to simulate the physiologic fate of insulin. The use of pro-drugs (insulin-

polymer conjugation), micelles, liposomes, solid lipid nanoparticles (NPs), and NPs made of biodegradable polymers are examples of nanomedicine technologies that could be used for oral insulin delivery.

Due to its simplicity in chemical modification and advantageous biological features, chitosan—a derivative of chitin, a naturally structural polymers found in crustaceans and fungi—is one of the natural polymers utilised for oral insulin delivery.

Pectin-insulinatpH3 was combined to create calcium pectinate-insulin nanoparticles (NPs).

With increased glucose tolerance, greater serum insulin (70%), lower blood glucose (29%), lower non-esterified fat acids (40%) and lower triglycerides (48%), oral treatment with zinc oxide NPs had also substantial antidiabetic benefits.

To shield insulin from gastrointestinal enzymes, a matrix-like system should be used. The insulin molecules can be contained in polymeric nanoparticles to accomplish this (PNPs). In one such investigation, insulin-loaded PNP pellets were used to orally administer insulin to diabetic rats. As a result of the delivery of insulin via the buccal route, the results revealed a considerable drop in blood sugar levels.

PNPs for parentral Insulin Administration:

For more than 40 years, polymeric materials have indeed been utilised in a variety of pharmaceutical or biotechnology applications. 31 PNPs were solid, colloidal particles with sizes ranging from 10 nm to 1000 nm that are made up of macromolecules. 32 Depending on the preparation techniques, NPs can be either nanospheres or nanocapsules.

Generally speaking, "controlled release systems" refers the technologies or biomaterials which are designed to release medications in predetermined and/or tuneable rates, or even in response to triggers and external stimuli. Due to their distinctive physico-chemical, synthetic, biocompatible, and degrading qualities, polymeric materials have become an important class for controlled release systems. These properties can be easily changed using tried-and-true methods.

Biodegradable PNPs have indeed been employed as insulin carriers, with the insulin matrix being encircled by a membrane with grafted glucose oxidase. An increase in blood glucose levels causes the nearby nanoporous membrane to alter, which leads to biodegradation & subsequent insulin administration. The pH in the microenvironment of the delivery system is lowered as a result of the glucose/glucose oxidase reaction. The polymer system may inflate more as a result, which could boost the release of insulin. The first study of this kind on smart cells' drug delivery was published in 2003.

Insulin Delivery Through Inhalable Nanoparticles:

The use of the lungs as a primary drug delivery channel for both systemic or local treatments has once again gained popularity thanks to nanotechnology. Drug transport may be aided by the lung's high alveolar surface area, thin epithelial barrier, and substantial vascularization. The mass mean aerodynamic dimension is typically used to indicate the sizes of the particles utilised in inhalation treatment. Inhaled insulin formulation have had more success when they are produced in the right size range.

The two primary categories of inhaled products are powdered formulations and solutions, both of which are given via various inhaler systems. As a result, when inhaling the powder form formulation of insulin, all insulin molecules could be delivered into to the lungs by being enclosed within the NP sand. Patients with both types of diabetes were investigated with Exubera®, which contains rapid-acting insulin in dry powder. Exubera's dry-powder inhaler method for insulin administration in phase III clinical trials showed that inhaled insulin formulations given before meals is just as effective as insulin injections given at mealtimes.

Intranasal Insulin Delivery:

A study found that nasal injection of gold nanoparicles (GNPs) containing insulin and decreased chitosan enhanced the pharmacodynamic action of insulin. Poor permeability all across mucosal membrane and a quick

mucociliary clearance mechanism which flushes out non-mucoadhesive formulations from of the absorption site are the main factors limiting overall bioavailability of nasally given insulin. Mucoadhesive NPs composed of chitosan/tripolyphosphate or starch have been investigated as a solution to these drawbacks. These NPs demonstrated good insulin-loading ability, releasing 75% to 80% of the insulin within 15 minutes of injection.

Transdermal Insulin:

The needle-free alternative of transdermal insulin delivery eliminates the drawbacks of other alternative routes, including the pulmonary or nasal routes. The main obstruction to the penetration of insulin to levels that are helpful is indeed its stratum corneum, the top layer of skin. It has also been claimed that microneedles work well as transdermal methods for delivering insulin. Compounds that are tiny and lipophilic molecules only can permeate. In order to break down the stratum corneum barrier and increase insulin permeability in the skin, a number of physical and chemical enhancement techniques have been investigated, including iontophoresis, ultra-sound/sonophoresis, micro-needles, electrical portion, laser ablation, as well as chemical enhancers.

Engineering fluorescent micro/nano size devices for glucose sensing is achievable. Using micro/NPs in the dermis could enable transdermal monitoring of interstitial fluid glucose fluctuations.

Biological micro electro mechanical systems for insulin delivery:

When blood glucose levels rise, implanted biology micro electrical mechanical systems (BioMEMS) could be employed as insulin pumps to release insulin under control. With prospects in fields including biosensors, pacemakers, immunological isolation capsule, and drug delivery, interest in bio MEMS is exploding. An insulin molecule-filled medication reservoir compartment is part of a bioMEMS device. Outside, there are biosensors or nonporous membranes with 6-nm-diameter pores that are used to monitor changes to blood glucose levels and trigger the release of insulin. The ability to utilise the properties of responsive hydrogels for sensing or valving applications is thus made possible by the small size scale of MEMS. For in vivo sensing applications, hydrogels that swell is response to changes of osmotic pressure, pH, and temperature analyte concentration may be very helpful.

Conclusion:

As the illness has multiple underlying causes, there is only one permanent treatment. Diabetes treatment options include diet, medication, islet cell transplantation, and stem cell therapy. Controlling one's diet appeared to help lower pancreatic One of the most common non-communicable diseases is diabetes. Insulin release and triglyceride content are still absent. Controlling diabetes and its consequences can lessen patients' suffering and boost the economy by reducing the huge sums of money needed on diabetic research, diagnosis, care, and therapy. Information from case studies demonstrates that diabetologists are becoming increasingly concerned about the rising number of people with diabetic complications. Information from the case study demonstrates the essential necessity of early intervention or care of diabetes patients. The current review provides context by going through recent developments in diabetes, including its classification, diagnosis, treatment options, and case study for managing regular diabetes.

Reference:

1) R. Deepa, S. Sandeep, V. Mohan et al., “Abdominal obesity, visceral fat and type 2 diabetes—Asian Indian phenotype,” in Type2 Diabetes in South Asians: Epidemiology, Risk Factors and Prevention, V. Mohan and G.H.R.Rao,Eds.,pp.138–152,Jaypee Brothers Medical Publishers, New Delhi,India,2006.
2) Indian Council of Medical Research, http://www.icmr.nic.in/.
3) Madras Diabetes Research Foundation (India), 2014, http:// mdrf.in/.
4) S. R. Joshi, “Metabolic syndrome—emerging clusters of the Indian phenol type,” Journal of Association of Physicians of India, vol. 51, pp. 445–446, 2003.
5) J. B. Buse, “Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy,”Diabetes Care, vol.22,pp. 65–70,1999.
6) American Diabetes Association, “Diagnosis and classification of diabetes mellitus,”Diabetes Care, vol.33, supplement1,pp. S62–S69,2010.
7) Y.-H. Chen, B. Feng, and Z.-W. Chen, “Statin for primary prevention of cardiovascular and cerebro

vascular events in diabetic patients without established cardiovascular diseases: ameta- analysis," Experimental and Clinical Endocrinology and Diabetes, vol.120, no.2,pp.116– 120,2012.
8) J.Buse,"Stat intreatmentin diabetes mellitus, "Clinical Diabetes, vol.21,no.4,pp.168– 172,2003
9) J.G.Pastors,H.Warshaw,A.Daly,M.Franz,andK.Kulkarni, "The evidence for the effectivenessof medical nutrition therapy in diabete smanagement,"Diabetes Care,vol.25,no.3,pp.608–613,2002.